Skip to content
MarketScale
‹ Back to IndustriesHealthcare

The U.K. Bans Microbeads

If you’ve ever exfoliated your skin or brushed your teeth with toothpaste, you’ve probably used a microbead. Microbeads are the tiny plastic spheres found in many exfoliating facial scrubs, shower gels, toothpastes and other rinse-off skincare products on the market. They are in the class of microplastics, pieces of plastic less than five millimeters, or…

This story was produced through MarketScale. See how Healthcare teams put it to work with Executive Thought Leadership.

Share

If you’ve ever exfoliated your skin or brushed your teeth with toothpaste, you’ve probably used a microbead. Microbeads are the tiny plastic spheres found in many exfoliating facial scrubs, shower gels, toothpastes and other rinse-off skincare products on the market. They are in the class of microplastics, pieces of plastic less than five millimeters, or 0.2-inches, long. Found in chewing gum, glitter, industrial cleaning products, synthetic clothing fibers and even tires, microplastics are everywhere, and that’s a big problem for the world’s oceans.

Because they’re so small, microbeads cannot be filtered out by wastewater treatment plants and end up in the watershed. From there, they are inadvertently eaten by fish and other marine animals—the very fish and marine animals that are an important part of the food chain. This means humans ultimately end up eating the very plastic they were using to wash their faces. This can cause hormone disruptions and cancer. In response to health concerns, the U.K. government pledged to ban the manufacturing of cosmetic products containing microbeads in 2016. The ban just took effect on January 8, 2018 and joins similar bans enacted by the U.S., Canada, and New Zealand.

While this move is certainly a positive for the world’s ocean ecosystems and our own food chain, plastic in its many forms remains a problem for the environment, for ocean animals, and for our own health. Some municipalities are looking to tax or ban plastic grocery bags or plastic-coated cups, and leaders are calling for a reduction in the use of bottled water packaged in plastic.

Healthcare: are you visible to AI?

Before they reach out, Healthcare buyers ask AI engines which vendors to trust. See how AI describes your company today, and where competitors show up instead.

Free workspace

You just read one Healthcare expert. Imagine publishing your whole team.

This article was produced through MarketScale. Create a free workspace and turn your own team's Healthcare expertise into the articles, video, and social content B2B marketing buyers in your industry are searching for. No credit card, no demo required.

NPS +73 · 1,000+ creators · 38+ countries

What you get, free

Your own MarketScale Studio workspace
One video edit a month, on us
AI writing, editing, and publishing tools
In-platform coaching to learn the system

More Healthcare Insights

Rebuilding Medicine Around Presence: The Future of Physician House Calls with Dr. Yevhen Pavelko, Founder of Inviah Health

Dr. Yevhen Pavelko, founder of Inviah Health, is advocating for the resurgence of physician house calls. He believes that personal interaction can significantly improve patient care and satisfaction. Inviah Health aims to modernize this traditional approach by integrating advanced medical technology.

  • 01Dr. Yevhen Pavelko supports the revival of physician house calls to improve patient care.
  • 02Inviah Health focuses on integrating advanced technology with traditional house call practices.
  • 03Personal interaction between doctors and patients can enhance care and satisfaction.

Jul 31, 2026

Tempus AI's $1.7B Personalis deal leads a surge in health-tech M&A that is already reshaping vendor choices for health system operators

Tempus AI's $1.7B Personalis deal leads a surge in health-tech M&A that is already reshaping vendor choices for health system operators

Digital health mergers and acquisitions (M&A) along with venture capital (VC) activities are rapidly increasing. Tempus AI's $1.7 billion acquisition of Personalis is part of a larger trend that is influencing health system operators’ selection of vendors. With $7.4 billion in funding during the first half of 2026, the health-tech industry is undergoing significant transformation.

  • 01Tempus AI acquired Personalis for $1.7 billion.
  • 02Health-tech received $7.4 billion in funding in the first half of 2026.
  • 03M&A activities are influencing vendor choices for health system operators.

Jul 30, 2026

Digital health AI investment hits $7.4B in H1 2026 as CMS, hospitals, and startups all accelerate adoption

Digital health AI investment hits $7.4B in H1 2026 as CMS, hospitals, and startups all accelerate adoption

In the first half of 2026, digital health AI investments reached $7.4 billion as organizations like CMS, hospitals, and startups increased their adoption of AI. Significant moves include the establishment of a new CMS technology office and a $1.7 billion acquisition in cancer technology. These developments mark an enterprise-level commitment to advancing AI in healthcare.

  • 01Digital health AI investments reached $7.4 billion in H1 2026.
  • 02The CMS established a new technology office to advance healthcare AI.
  • 03A major acquisition in cancer technology totaled $1.7 billion.

Jul 30, 2026

Explore More Healthcare Insights

Read more expert perspectives from across Healthcare.

Browse Healthcare Hub

For B2B teams

Your experts could be publishing here

Stories like this one run on content MarketScale captures from real practitioners. See how your team's expertise becomes coverage in Healthcare and beyond.

Book a 15-minute demo

Or call us. No forms required. We pick up. 214-945-2512